新型冠状病毒感染与肠道微生态的相关性研究

Correlation between infection of SARS-CoV-2 and intestinal microecology

新型冠状病毒肺炎是当今世界范围内的主要流行病,新型冠状病毒感染患者除了肺部症状外,还有部分伴发消化道症状,新型冠状病毒的受体ACE2在肠道上皮细胞也同样表达,且肠道菌群在多种肺部疾病中的作用也已被很好地阐明。新型冠状病毒肺炎肺部病变的病理生理机制可能与肠道菌群的改变相关。临床上可以通过给予患者微生态制剂或ACE2抑制剂的方式,维护患者肠道微生态的稳定,缓解重型患者和老年患者的病情,为新型冠状病毒肺炎的治疗与预防提供新思路。

COVID-19 is a major epidemic around the world.In addition to pulmonary symptoms,some patients with infection of SARS-CoV-2 are also associated with digestive tract symptoms.Receptor of SARS-CoV-2,ACE2,is also expressed on intestinal epithelial cells,and the effect of gut microbiota on a variety of pulmonary diseases has been well elucidated.The pathophysiological mechanism of pulmonary pathological changes in COVID-19 may be related to the changes of gut microbiome.In clinical practice,microecologics or ACE2 inhibitors can be given to patients to maintain the stability of intestinal microecology and alleviate the condition of severe patients as well as elderly patients,which provide a new direction for the treatment and prevention of COVID-19.